AtaCor Medical

AtaCor Medical is committed to transforming cardiac rhythm management by developing extravascular lead and deployment systems that preserve the integrity of the heart and vasculature. The company's core innovation is a parasternal lead system designed to work with commercially available ICDs, offering a potentially safer alternative to transvenous and subcutaneous ICDs. Led by a seasoned team with deep experience in cardiac rhythm management, including veterans from the S-ICD development, AtaCor is backed by a syndicate of leading life science venture capital firms and is advancing its technology through clinical development.

A parasternal extravascular lead placement platform designed to deliver defibrillation and antitachycardia pacing therapy from outside the heart and vasculature, compatible with commercially available implantable cardioverter-defibrillator (ICD) generators.

Total raised: $35M

Main competitors are the dominant transvenous ICD manufacturers (Medtronic, Abbott, Boston Scientific) and Boston Scientific's subcutaneous ICD (S-ICD). AtaCor aims to differentiate by providing an extravascular system capable of both defibrillation and antitachycardia pacing, a combination not currently available outside the transvenous approach.